CD274 and breast carcinoma: The antitumor immune response mediated by the programmed death 1/programmed death ligand 1 (PD1/PD-L1) and cytotoxic T lymphocyte antigen-4 inhibitors provides a proof-of-principle for immunotherapy use in breast cancer [95].